The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2015

Filed:

Jul. 21, 2008
Applicants:

Ralf Hoffmann, Grosspösna, DE;

Patricia Czihal, Leipzig, DE;

Inventors:

Ralf Hoffmann, Grosspösna, DE;

Patricia Czihal, Leipzig, DE;

Assignee:

AMP-THERAPEUTICS GMBH, Leipzig, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 7/08 (2006.01); A61K 38/00 (2006.01); A01N 37/46 (2006.01); A01N 63/02 (2006.01);
U.S. Cl.
CPC ...
A01N 37/46 (2013.01); A01N 63/02 (2013.01); A61K 38/00 (2013.01); C07K 7/08 (2013.01);
Abstract

This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide derivates have the general formula Sub-XN XXP V Y I P XXR P P H P-Sub(SEQ ID NO:) wherein Xis a neutral or positively charged moiety, Xis a polar or positively charged moiety, Xis a positively charged moiety, Xis a polar or positively charged moiety, Xis a proline or a proline derivate, Subbeing the free or modified N-terminus, and Subbeing the free or modified C-terminus. The peptides or peptide derivates according to the invention possess at least one of the following advantages compared to the natural occurring apidaecin peptides: (i) an increased half-live in mammalian serum due to a higher protease resistance and (ii) an increased antimicrobial activity against one or several bacterial strains, especially human pathogens, or fungus or other microbial infections (iii) show an enlarged spectrum of antimicrobial activity, (iv) do induce less resistance in microbes and (v) are not toxic to human cells including erythrocytes.


Find Patent Forward Citations

Loading…